No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 2008, Pages 95-100

  Nakade, Susumu ^a   Ohno, Tomoya ^a   Nakayama, Kazuki ^a   Kitagawa, Junsaku ^a   Hashimoto, Yoshitaka ^a   Ohnishi, Akihiro ^b   Miyata, Yasuyuki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Digoxin; Drug drug interaction; Imidafenacin; Pharmacokinetics

Indexed keywords

DIGOSIN; DIGOXIN; IMIDAFENACIN; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG URINE LEVEL; EVENING DOSAGE; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; INTERVERTEBRAL DISK DEGENERATION; JAPAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NECK PAIN; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; XEROSTOMIA; DRUG INTERACTION;

ADULT; CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; MALE; MUSCARINIC ANTAGONISTS;

EID: 43749086433     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.95     Document Type: Article

References (18)

1. Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U. et al.: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology, 61: 37-49 (2003).
2. Liberman, J. N., Hunt, T. L., Stewart, W. F., Wein, A., Zhou, Z., Herzog, A. R. et al.: Health-related quality of life among adults with symptoms of overactive bladder: results from a US community based survey. Urology, 57: 1044-50 (2001).
3. Stewart, W. F., Van Rooyen, J. B., Cundiff, G. W., Abrams, P., Herzog, A. R., Corey, R. et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol., 20: 327-36 (2003).
4. Hu, T. W., Wagner, T. H., Bentkover, J. D., LeBlanc, K., Piancentini, A., Stewart, W. F. et al.: Estimated economic costs of overactive bladder in the United States. Urology, 61: 1123-8 (2003).
5. Wein, A. J. and Rovner, E. S.: The overactive bladder: an overview for primary care health providers. Int. J. Fertil. Womens Med., 44: 56-66 (1999).
6. Miyachi, H., Kiyota, H., Uchiki, H. and Segawa, M.: Synthesis and Antimuscarinic Activity of a Series of 4-(1-Imidazolyl)-2,2-diphenylbutyramode: Discovery of Potent and Subtype-selective Antimuscarinic Agents., Bio. Med. Chem., 7: 1151-1161 (1999).
7. Ohno, T., Nakade, S., Nakayama, K., Kitagawa, J., Ueda, S., Miyabe, H., et al.: Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br. J. Clin. Pharmacol., accepted.
8. Shimada, H., Yafune, A., Shibata, H., Hirahara, Y. and Masuda, Y.: Phase I clinical study of imidafenacin (KRP-197/ONO-8025): single-dose safety and pharmacokinetics of imidafenacin in healthy subjects. J. Clin. Therap. Med., 23: 233-248 (2007).
9. Shimada, H., Hasunuma, T., Hirahara, Y. and Ishikawa, N.: Pharmacokinetic study of imidafenacin (KRP-197/ONO-8025): pharmacokinetics of single oral administration of imidafenacin tablet 0.1 mg and food-effect on its oral absorption in healthy male volunteers. J. Clin. Therap. Med., 23: 273-285 (2007).
10. Shimada, H., Shibata, H., Hirahara, Y. and Masuda, Y..: Investigation on safety and pharmacokinetic profile of imidafenacin (KRP-197/ONO-8025) after single administration in the eldery. J. Clin. Therap. Med., 23: 263-272 (2007).
11. Kanayama, N., Kanari, C., Masuda, Y., Ohmori, S. and Ooie, T.: Drug-drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica, 37: 139-154 (2007).
12. Manninen, V., Apajalahti, A., Melin, J. and Karesoja, M.: Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet, 301: 398-400 (1973).
13. Brown, D. D., Schmid, J., Long, R. A. and Hull, J. H.: A steadystate evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J. Clin. Pharmacol., 25: 360-364 (1985).
14. Masuda, Y., Kanayama, N., Manita, S., Ohmori, S. and Ooie, T.: Development and validation of bioanalytical methods for imidafenacin (KRP-197/ONO-8025and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr., 21: 940-948 (2007).
15. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling (Draft). Rockville, MD: Food and Drug Administration (2006).
16. Andersson, K. E.: Antimuscarinics for treatment of overactive bladder. Lancet Neurol., 3: 46-53 (2004).
17. Kobayashi, F., Yageta, Y., Segawa, M. and Matsuzawa, S.: Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung., 57: 92-100 (2007).
18. Ohno, T., Nakayama, K., Nakade, S., Kitagawa, J., Ueda, S., Miyabe, H., et al.: Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects. J. Clin. Pharmacol., accepted.